Last reviewed · How we verify
Low Dose TP-05
At a glance
| Generic name | Low Dose TP-05 |
|---|---|
| Also known as | Lotilaner |
| Sponsor | Tarsus Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05 (PHASE2)
- Study to Evaluate the Food Effect of TP-05 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low Dose TP-05 CI brief — competitive landscape report
- Low Dose TP-05 updates RSS · CI watch RSS
- Tarsus Pharmaceuticals, Inc. portfolio CI